Ignite Creation Date:
2024-10-25 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06599463
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-11
Brief Title:
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer a French Multicentric Retrospective Early Access Program-based Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer a French Multicentric Retrospective Early Access Program-based Study
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LARENA
Brief Summary:
LARENA is a multicentric retrospective study secondary use of data of consecutive patients prospectively registered in the lenvatinib plus pembrolizumab French early access program Temporary Authorisation for Use The source of data will be the patients medical file We will manually review all files of the participating centers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None